Actively Recruiting
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Led by Nordic Society of Gynaecological Oncology - Clinical Trials Unit · Updated on 2026-02-27
1000
Participants Needed
1
Research Sites
500 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.
CONDITIONS
Official Title
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18 years or older at diagnosis
- Newly diagnosed epithelial ovarian cancer confirmed by tissue analysis
- FIGO stage I-II ovarian cancer with known BRCA1/2 mutation (germline or somatic)
- FIGO stage III-IV ovarian cancer of any histology
- Planned treatment with platinum-based chemotherapy
- Able to provide signed informed consent
- Agree to provide archival tumor tissue sample
You will not qualify if you...
- Non-epithelial ovarian cancer, borderline tumors, or mucinous histology
- FIGO stage I-II ovarian cancer without BRCA1/2 mutation (BRCA wild type)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rigshospitalet
København Ø, Region Sjælland, Denmark, 2100
Actively Recruiting
Research Team
K
Kristine Madsen, MD
CONTACT
H
Henriette W Hansen, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here